Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Prices Public Offering

NEW YORK (GenomeWeb News) – Beckman Coulter today said that it would offer 4.5 million shares of its common stock for $53 per share in a public offering.

The firm announced yesterday that it had filed for the offering, along with pricing two notes offerings. Beckman said that it priced $250 million worth of senior notes that mature in 2015 at a rate of 6 percent, and it priced $250 million worth of senior notes that mature in 2019 at a rate of 7 percent. Those debt offerings are expected to close on May 21.

Under the public stock offering, Beckman entered into forward sale agreements with Morgan Stanley and Goldman Sachs, under which the banks will borrow and sell to underwriters of the offering the 4.5 million shares. The shares will then be offered to the public at a price of $53 per share.

Beckman said that it expects to receive gross proceeds of $238.5 million upon settlement of the forward sale agreements and before deducting the underwriters' discount and estimated offering expenses. There also is an over-allotment option of 450,000 common shares.

Beckman will use the funds from the public stock and notes offerings to pay for its $780 million acquisition of Olympus' diagnostics business.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.